Sino Biopharmaceutical Limited (SINOBIOPHARM) cash flow statement
HKSE · Healthcare · Medical - Pharmaceuticals · 22,838 employees · CEO S. Y. Tse
- Price
- HK$4.86 +0.83%
- Market cap
- HK$86.5B
- Enterprise value
- CN¥75.5B
- Last report
- Q2 '26 filed 2026-06-30
- Next report
- 2027-04-01
In Q2 '26 Sino Biopharmaceutical Limited (SINOBIOPHARM) generated CN¥0 of operating cash flow, invested CN¥0 in capital expenditure and kept CN¥0 of free cash flow. Over the last four quarters free cash flow was CN¥5.16B.
Cash flow
| Cash flow | Trend | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||||
| Net income | CN¥629M | CN¥0 | CN¥1.51B | CN¥1.51B | CN¥241M | CN¥241M | CN¥1.69B | CN¥1.69B | -CN¥523M | -CN¥523M | CN¥1.72B | CN¥1.72B | |
| Depreciation & amortization | CN¥315M | CN¥0 | CN¥255M | CN¥255M | CN¥305M | CN¥305M | CN¥288M | CN¥288M | CN¥318M | CN¥318M | CN¥273M | CN¥273M | |
| Stock-based compensation | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥26.9M | CN¥26.9M | CN¥0 | CN¥0 | CN¥58M | CN¥58M | CN¥42.5M | CN¥42.5M | |
| Change in working capital | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥1.8B | CN¥1.8B | CN¥0 | CN¥0 | |
| Other non-cash items | CN¥391M | CN¥0 | -CN¥224M | -CN¥224M | -CN¥573M | -CN¥573M | -CN¥402M | -CN¥402M | CN¥1.41B | CN¥1.41B | -CN¥2.03B | -CN¥2.03B | |
| Operating cash flow | CN¥1.34B | CN¥0 | CN¥1.54B | CN¥1.54B | CN¥0 | CN¥0 | CN¥1.58B | CN¥1.58B | CN¥3.07B | CN¥3.07B | CN¥0 | CN¥0 | |
| Investing | |||||||||||||
| Capital expenditure | -CN¥377M | CN¥0 | -CN¥204M | -CN¥204M | CN¥0 | CN¥0 | -CN¥135M | -CN¥135M | -CN¥484M | -CN¥484M | CN¥0 | CN¥0 | |
| Acquisitions | CN¥229K | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | -CN¥2.51B | -CN¥2.51B | CN¥0 | CN¥0 | |
| Other investing | -CN¥1.66B | CN¥0 | -CN¥817M | -CN¥817M | CN¥0 | CN¥0 | -CN¥3.51B | -CN¥3.51B | CN¥433M | CN¥433M | CN¥0 | CN¥0 | |
| Investing cash flow | -CN¥2.04B | CN¥0 | -CN¥1.02B | -CN¥1.02B | CN¥0 | CN¥0 | -CN¥3.64B | -CN¥3.64B | -CN¥2.56B | -CN¥2.56B | CN¥0 | CN¥0 | |
| Financing | |||||||||||||
| Share buybacks | -CN¥118M | CN¥0 | -CN¥181M | -CN¥181M | CN¥0 | CN¥0 | -CN¥55M | -CN¥55M | -CN¥1.5K | -CN¥1.5K | CN¥0 | CN¥0 | |
| Dividends | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | -CN¥751M | -CN¥751M | CN¥0 | CN¥0 | |
| Other financing (incl. tax on vested shares) | -CN¥1.9B | CN¥0 | -CN¥1.87B | -CN¥1.87B | CN¥0 | CN¥0 | CN¥843M | CN¥843M | CN¥2.04B | CN¥2.04B | CN¥0 | CN¥0 | |
| Financing cash flow | -CN¥2.02B | CN¥0 | -CN¥2.05B | -CN¥2.05B | CN¥0 | CN¥0 | CN¥788M | CN¥788M | CN¥1.29B | CN¥1.29B | CN¥0 | CN¥0 | |
| Summary | |||||||||||||
| FX effect on cash | CN¥42.4M | CN¥0 | CN¥13.1M | CN¥13.1M | CN¥0 | CN¥0 | -CN¥14.8M | -CN¥14.8M | CN¥73.8M | CN¥73.8M | CN¥0 | CN¥0 | |
| Net change in cash | -CN¥2.68B | -CN¥3.29B | -CN¥1.52B | -CN¥1.52B | -CN¥4.47B | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | |
| Free cash flow (OCF - capex) | CN¥959M | CN¥0 | CN¥1.34B | CN¥1.34B | CN¥0 | CN¥0 | CN¥1.44B | CN¥1.44B | CN¥2.58B | CN¥2.58B | CN¥0 | CN¥0 | |
| Interest paid | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥137M | CN¥137M | CN¥0 | CN¥0 | |
| Cash flow | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Net income | CN¥3.35B | CN¥4.2B | CN¥11.4B | CN¥5.58B | CN¥5.01B | CN¥18.6B | CN¥5.78B | CN¥5.93B | CN¥6.99B | CN¥6.94B | |
| Depreciation & amortization | CN¥317M | CN¥343M | CN¥1.18B | CN¥1.47B | CN¥1.65B | CN¥993M | CN¥1.05B | CN¥1.07B | CN¥1.32B | CN¥1.21B | |
| Stock-based compensation | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥29.7M | CN¥18.1M | CN¥53.7M | CN¥116M | |
| Change in working capital | CN¥323M | CN¥431M | CN¥243M | -CN¥279M | CN¥261M | -CN¥339M | -CN¥196M | -CN¥431M | CN¥99.8M | CN¥2.62B | |
| Other non-cash items | -CN¥901M | -CN¥1.24B | -CN¥7.75B | -CN¥1.45B | -CN¥1.6B | -CN¥13.9B | -CN¥395M | -CN¥530M | -CN¥1.85B | -CN¥1.6B | |
| Operating cash flow | CN¥3.09B | CN¥3.73B | CN¥5.09B | CN¥5.32B | CN¥5.33B | CN¥5.37B | CN¥6.27B | CN¥6.07B | CN¥6.62B | CN¥9.29B | |
| Investing | |||||||||||
| Capital expenditure | -CN¥935M | -CN¥1.46B | -CN¥1.69B | -CN¥1.73B | -CN¥1.86B | -CN¥1.89B | -CN¥1.71B | -CN¥1.07B | -CN¥960M | -CN¥1.24B | |
| Acquisitions | -CN¥28.3M | -CN¥288M | CN¥1.2B | -CN¥222M | -CN¥4.2B | -CN¥959M | -CN¥58.5M | -CN¥743M | CN¥1.41B | -CN¥5.3B | |
| Purchases of investments | -CN¥1.37B | -CN¥1.41B | -CN¥2.45B | -CN¥2.89B | -CN¥7.16B | -CN¥4.85B | -CN¥4.48B | -CN¥1.65B | -CN¥5.44B | -CN¥8.13B | |
| Sales / maturities of investments | CN¥142M | CN¥419M | CN¥2.17B | CN¥914M | CN¥5.12B | CN¥903M | CN¥1.08B | CN¥2.56B | CN¥1.72B | CN¥521M | |
| Other investing | CN¥135M | CN¥760M | CN¥160M | CN¥112M | CN¥250M | CN¥4.28B | CN¥1.1B | CN¥142M | CN¥1.57B | CN¥1.74B | |
| Investing cash flow | -CN¥2.05B | -CN¥1.98B | -CN¥616M | -CN¥3.82B | -CN¥7.85B | -CN¥2.52B | -CN¥4.07B | -CN¥757M | -CN¥1.71B | -CN¥12.4B | |
| Financing | |||||||||||
| Net debt issued / repaid | CN¥1.6B | -CN¥97.2M | CN¥305M | CN¥5.2B | CN¥5.39B | -CN¥1.64B | CN¥1.05B | -CN¥1.75B | -CN¥2.74B | CN¥6.38B | |
| Share buybacks | CN¥0 | CN¥0 | -CN¥604M | -CN¥32.1M | -CN¥195M | -CN¥333M | -CN¥868M | -CN¥396M | -CN¥1.25B | -CN¥110M | |
| Dividends | -CN¥376M | -CN¥450M | -CN¥710M | -CN¥820M | -CN¥1.19B | -CN¥938M | -CN¥1.27B | -CN¥633M | -CN¥1.85B | -CN¥1.5B | |
| Other financing (incl. tax on vested shares) | -CN¥659M | -CN¥799M | -CN¥1.17B | -CN¥1.55B | -CN¥1.77B | -CN¥316M | -CN¥2.1B | -CN¥3.77B | -CN¥632M | -CN¥614M | |
| Financing cash flow | CN¥567M | -CN¥1.35B | -CN¥2.18B | CN¥2.8B | CN¥2.23B | -CN¥3.23B | -CN¥3.19B | -CN¥6.55B | -CN¥6.32B | CN¥4.16B | |
| Summary | |||||||||||
| FX effect on cash | -CN¥216M | -CN¥218M | CN¥242M | CN¥95.1M | CN¥280M | -CN¥650M | CN¥47.3M | CN¥90.5M | CN¥136M | CN¥118M | |
| Net change in cash | CN¥1.23B | CN¥190M | CN¥2.54B | CN¥4.4B | -CN¥7.02M | -CN¥1.02B | -CN¥945M | -CN¥1.15B | -CN¥1.27B | CN¥1.15B | |
| Free cash flow (OCF - capex) | CN¥2.16B | CN¥2.27B | CN¥3.4B | CN¥3.59B | CN¥3.47B | CN¥3.47B | CN¥4.56B | CN¥4.36B | CN¥5.22B | CN¥7.59B | |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsShare count and EPS
quarterly, dilutedThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings.
Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.